ResMed reported quarterly EPS of $2.86, topping the Zacks Consensus Estimate of $2.79 by $0.07, and up from $2.37 a year ago. The result indicates solid earnings momentum and a modest positive surprise versus analyst expectations.
ResMed reported quarterly EPS of $2.86, topping the Zacks Consensus Estimate of $2.79 by $0.07, and up from $2.37 a year ago. The result indicates solid earnings momentum and a modest positive surprise versus analyst expectations.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
mildly positive
Sentiment Score
0.34
Ticker Sentiment
